Ingevity (NYSE:NGVT) CEO David Li Sells 5,000 Shares of Stock

Key Points

• CEO David Li sold 5,000 Ingevity shares at an average price of $75.83, generating $379,150 under a pre-arranged Rule 10b5-1 trading plan. His remaining ownership fell 3.98% to 120,636 shares.
• Ingevity’s latest quarterly results exceeded expectations, with earnings of $1.74 per share versus the $1.33 consensus and revenue of $314.1 million. The company issued fiscal 2026 EPS guidance of $5.00–$5.45.
• Shares recently traded at $74.01, while analysts maintain a consensus “Hold” rating with an $80 target price. Institutional investors own 91.59% of the company’s stock.

Ingevity Corporation (NYSE:NGVT - Get Free Report) CEO David Li sold 5,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the transaction, the chief executive officer owned 120,636 shares of the company's stock, valued at approximately $9,147,827.88. This represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingevity Price Performance

Ingevity stock traded down $1.78 during mid-day trading on Tuesday, reaching $74.01. The company had a trading volume of 177,777 shares, compared to its average volume of 291,037. Ingevity Corporation has a fifty-two week low of $45.85 and a fifty-two week high of $79.29. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52. The company has a market cap of $2.54 billion, a P/E ratio of 50.34 and a beta of 1.16. The business has a fifty day simple moving average of $73.75 and a 200 day simple moving average of $71.72.

Ingevity (NYSE:NGVT - Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share for the quarter, topping analysts' consensus estimates of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The firm had revenue of $314.10 million for the quarter, compared to analysts' expectations of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, equities research analysts predict that Ingevity Corporation will post 5.4 earnings per share for the current year.

Institutional Investors Weigh In On Ingevity

A number of institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC raised its position in shares of Ingevity by 10.9% during the first quarter. AQR Capital Management LLC now owns 13,410 shares of the company's stock worth $518,000 after acquiring an additional 1,323 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Ingevity by 5.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,790 shares of the company's stock worth $863,000 after purchasing an additional 1,080 shares during the last quarter. Empowered Funds LLC lifted its position in shares of Ingevity by 12.9% in the 1st quarter. Empowered Funds LLC now owns 5,181 shares of the company's stock worth $205,000 after purchasing an additional 594 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Ingevity by 311.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company's stock valued at $23,769,000 after purchasing an additional 454,579 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Ingevity by 306.1% during the first quarter. Jane Street Group LLC now owns 88,883 shares of the company's stock worth $3,519,000 after buying an additional 66,995 shares during the period. Institutional investors own 91.59% of the company's stock.

Wall Street Analyst Weigh In

NGVT has been the subject of a number of research reports. Wall Street Zen lowered shares of Ingevity from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Ingevity currently has a consensus rating of "Hold" and a consensus target price of $80.00.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source